AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (1.3 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Publishing Language: Chinese | Open Access

Establishment and clinical application of the "three-stage and three-dimension" diagnosis and treatment system for metabolic-associated fatty liver disease

Jiayan HU1,2, Junxiang LI1, Tangyou MAO1( ), Yuxi WANG1,2, Zhengdao LIN1,2, Yitong YU1,2, Anqi YANG1,2
Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China
Graduate School of Beijing University of Chinese Medicine, Beijing 100029, China
Show Author Information

Abstract

Metabolic-associated fatty liver disease (MAFLD), a globally prevalent chronic liver disorder, is characterized by a dynamically progressive disease spectrum spanning simple hepatic steatosis, steatohepatitis, and hepatic fibrosis/cirrhosis. Although Western medicine has clarified its "multiple hits" pathogenesis, specific therapeutic strategies for MAFLD are lacking and primarily rely on lifestyle interventions and limited medications and pharmacotherapies. Although the traditional syndrome differentiation of Chinese medicine focuses on pathological factors, such as phlegm-dampness and blood stasis, it has certain limitations in systematically capturing the complex dynamic evolutionary process of this disease from functional disorder to organic damage, thereby limiting its clinical efficacy in prevention and treatment. This study proposes a core pathogenesis evolution law of MAFLD characterized by stagnation to impairment. It clarifies that the disease undergoes a three-stage dynamic progression following the stagnation pathway (qi movement stagnation)→ heat (turbid toxin transforming into heat)→ impairment (hepatic injury with fibrosis and mass formation). Our team have established a three-stage and three-dimension stereoscopic pathogenesis model, in which the vertical dimension delineates the temporal progression of the disease through the stagnation, heat, and impairment stages, and the horizontal dimension deciphers the core targets of each stage from three aspects: zang-fu viscera function, pathological factors, and collateral status, forming a spatiotemporally integrated pathogenesis analysis system. On this basis, we established a stage-specific diagnosis and treatment system featuring a three-step liver modulation strategy of dispersing stagnated liver qi, removing liver-fire, and nourishing the liver. We identified the representative herbal formulas corresponding to each stage. This three-stage, three-dimension diagnosis and treatment system achieved organic integration of pathogenesis understanding, syndrome differentiation, therapeutic principles and methods, and herbal formula application. It provides a novel theoretical framework and clinical approach for integrating Chinese and Western medicine to prevent and treat MAFLD, aiming to halt disease progression, improve patient prognosis, and address practical clinical challenges such as ambiguous disease staging, imprecise syndrome differentiation, and insufficient therapeutic targeting.

CLC number: R259

References

【1】
【1】
 
 
Journal of Beijing University of Traditional Chinese Medicine
Pages 537-543

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
HU J, LI J, MAO T, et al. Establishment and clinical application of the "three-stage and three-dimension" diagnosis and treatment system for metabolic-associated fatty liver disease. Journal of Beijing University of Traditional Chinese Medicine, 2026, 49(4): 537-543. https://doi.org/10.3969/j.issn.1006-2157.2026.04.011

519

Views

1

Downloads

0

Crossref

0

Scopus

0

CSCD

Received: 15 December 2025
Published: 30 April 2026
© 2026 Journal of Beijing University of Traditional Chinese Medicine